Zhou, ChunxianCui, FengyunLi, JialiWang, DiyiWei, YingzeWu, YingWang, JipingZhu, HongguangWang, Shuyang2017-11-212017Zhou, Chunxian, Fengyun Cui, Jiali Li, Diyi Wang, Yingze Wei, Ying Wu, Jiping Wang, Hongguang Zhu, and Shuyang Wang. 2017. “MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway.” Oncotarget 8 (30): 49534-49547. doi:10.18632/oncotarget.17743. http://dx.doi.org/10.18632/oncotarget.17743.http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375129Although 5-year survival rate of non-metastatic colorectal cancer (CRC) is high, about 10% of patients in stage I and II still develop into metastatic CRC and eventually die after resection. Currently, there is no effective biomarker for predicting the prognosis of non-metastatic CRC in clinical practice. In this study, we identified miR-650 as a biomarker for prognosis prediction. We observed that the expression of miR-650 in tumor tissues had a positive association with overall survival. MiR-650 inhibited cell growth and invasion in vitro and in vivo. Furthermore, miR-650 targeted AKT2 and repressed the activation of the AKT pathway (AKT2/GSK3β/E-cadherin). Thus it induced the translocation of E-cadherin and β-catenin in cancer cells. Our results highlight the potential of miR-650 as a prognostic prediction biomarker and therapeutic target in non-metastatic CRC via inhibition of the AKT2/GSK3β/E-cadherin pathway.en-USnon-metastatic colorectal cancerprognosis biomarkermicroRNAAKT pathwayJournal Article2017-11-2110.18632/oncotarget.17743